MESI is a heterogeneous spectrum of diseases with a common clinical presentation and a common pathophysiology. KSI-101 has the potential to become the first line common therapy for MESI Macular Edema Blood Retinal Barrier Disruption VEGF IL-6 IL-6 KSI-101 Common Clinical Presentation Common Pathophysiology Potential common therapy Angiogenesis Inflammation Normal Retina after a single injection of KSI-101 10 mg 100